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Abstract
Context The usefulness of stool calprotectin determina-
tion in diagnosis of inflammatory disease of the colon has
been reported; information about its usefulness for patients
with polyposis are scarce, however.
Objective To evaluate the significance of stool calpro-
tectin concentrations for patients affected by colonic
polyposis.
Patients Sixty-three consecutive patients (35 males, 28
females, mean age 60.3 years, range 39–78 years) were
enrolled: 26 patients (41.3%) with polyps, 17 patients
(27.0%) with asymptomatic diverticular disease, and 20
subjects (31.7%) with normal endoscopic appearance of the
colon.
Results Stool calprotectin concentrations were
17.4 ± 24.5 lg g–1 for patients with colonic polyposis,
significantly higher than concentrations for patients with
diverticulosis (7.1 ± 5.7 lg g–1; P = 0.026) or for patients
with normal appearance of the colon (calprotectin
6.0 ± 5.8 lg g–1; P = 0.003). For patients with a single
polyp, stool calprotectin concentrations were similar to
those for patients with multiple polyps. Calprotectin fecal
concentrations for patients with sessile polyps and those
with flat polyps were not significantly different. Calpro-
tectin concentrations were not significantly related to the
size of the polyps.
Conclusion Our data show that colonic polyposis may
cause an increase in stool calprotectin values and that these
colonic lesions should be suspected when elevated stool
calprotectin concentrations are found.
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Introduction
Colorectal neoplasia is one of the most common malig-
nancies in the western world. The lifetime risk of colorectal
cancer in the US population is 5–6%. Over 50% of the
population will develop an adenomatous polyp by the age
of 70 years, even if only one tenth of these will proceed to
cancer [1]. Colon cancer detection at an early stage and the
possibility of identifying susceptible individuals could
result in reduced mortality from this neoplasia. Early rec-
ognition and removal of polyps currently has a significant
impact on reducing deaths from colon cancer [2]. There are
several accepted screening methods, including fecal occult
blood testing, sigmoidoscopy, double contrast barium
enema, virtual colonoscopy, and optical colonoscopy [3, 4]
but none is completely specific, sensitive, or reliable [5]. It
has also been demonstrated that inflammatory expression
increases gradually as epithelial cells progress through
dysplasia to neoplasia [6].
Calprotectin is a cytoplasmic antimicrobial compound
prominent in granulocytes, monocytes, and macrophages.
It accounts for approximately 60% of the total protein of
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the cytosol. Release of calprotectin is most probably a
consequence of cell disruption and death [7] and the
compound is stable in stools for more than 7 days at dif-
ferent temperatures and is resistant to proteolysis even after
transportation and storage [8]. Calprotectin can inhibit
bacterial proliferation as a component of the innate
immune response and through its iron-binding capacity [9].
Fecal calprotectin determination has been shown to be
useful in diagnosis of a variety of inflammatory diseases of
the gastrointestinal tract [10–14]; no data are available for
colonic polyposis, however, even though it is a common
disease of the colon. We therefore planned this prospective
study to determine the significance of stool calprotectin
concentrations in patients affected by colonic polyps.
Methods
Eligible patients eighteen year of age or older who
underwent colonoscopy for the first time at the Department
of Internal Medicine between February 2005 and February
2006 were enrolled. Patients in anticoagulant therapy,
those treated with anti-inflammatory drugs [15], heavy
alcohol drinkers [16], patients with rheumatoid arthritis,
cystic fibrosis, acute bacterial infections [17], and the
presence of known or suspected inflammatory bowel dis-
ease and colon cancer were excluded from the study. A
stool specimen was obtained from each subject enrolled in
the study three days before endoscopic examination and
before any administered bowel preparation. Laboratory
personnel were unaware of the clinical diagnoses or details
of the patients’ clinical histories. The stool specimens were
stored at –20C and calprotectin was assayed within four
weeks of collection. Calprotectin concentrations were
measured by use of a commercial ELISA kit (Calprotectin
ELISA Kit, Immundiagnostik, Bensheim, Germany) based
on a two-site sandwich technique with two selected
monoclonal antibodies which bind to human calprotectin.
Two 100-mg samples of feces from a single stool sample
from each participant were assayed, and the mean of the
two measurements was recorded. According to the manu-
facturer, the reference range was <15 lg g–1. The within-
run %CV (n = 20) was 9.1 at 10.7 lg g–1 and 4.2 at
22.2 lg g–1 and the between-run %CV (n = 12) was 12.3
at 9.9 lg g–1 and 6.1 at 22.5 lg g–1; the detection limit of
the test was 2.9 lg g–1. Colonoscopy was performed by a
single experienced endoscopist (GG) using an Olympus
colonoscope (CF-Q160Z I, Olympus Italia S.r.l., Segrate,
Italy). The cecum was reached and photographed in each of
the patients studied. The site and the number of polyps
identified during insertion and withdrawal using the col-
onoscope were recorded.
Ethics
The study was approved by the Clinical Committee of the
Department of Internal Medicine and all subjects gave
verbal informed consent to participate in the study.
Statistical analysis
Results are reported as mean ± SD, median, range, and
frequencies. The Shapiro–Wilk’s test of normality and the
Levene test for homogeneity of variance were applied: age
(P = 0.211, and P = 0.234, respectively) and BMI
(P = 0.090, and P = 0.399 respectively) did not require
transformation and logarithmic transformation was applied
to stool calprotectin values (before transformation:
P < 0.001, and P = 0.015, respectively; after transforma-
tion: P = 0.083, and P = 0.693, respectively). The data
were analyzed by one-way ANOVA (by applying the
simple contrast for pairwise comparisons), the v2 test, and
Pearson’s correlation. Statistical analysis was performed by
use of the Statistical Package for the Social Sciences for
Windows, version 13.0 (SPSS, Chicago, IL, USA), and a
two-tailed 0.05 P level was considered to be statistically
significant.
Results
Patients
Sixty-three consecutive patients (35 males, 28 females,
mean age 60.3 years, range 39–78 years) were enrolled in
this study. The patients were divided into three groups
according to final diagnosis. The first group (Polyposis)
contained 26 patients (41.3%) in whom a total of 43 polyps
were found. A single polyp was found in sixteen patients
(61.5%) and two or more polyps were found in ten patients
(38.5%) (two polyps in five patients, three polyps in four
patients, five polyps in one patient), thus the mean was
1.7 ± 1.0 polyps per patient. Polyp size was 8.1 ± 9.0 mm
with a median of 5 mm and the range was from 3 to
60 mm. Twenty-five polyps were sessile (58.1%), fifteen
were flat (34.9%), two were semipedunculate (4.7%), and
one was pedunculate (2.3%). Ten of the polyps were in the
ascending colon (23.3%), thirteen in the transverse colon
(30.2%), three in the descending colon (7.0%), twelve in
the sigmoid colon (27.9%), and the remaining five in the
rectum (11.6%). All the polyps were removed endoscopi-
cally and in no case was the histology indicative of cancer.
The second group (Diverticulosis) contained seventeen
patients (27.0%) with asymptomatic diverticular disease
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and the third group (Normal) contained twenty subjects
(31.7%) with normal endoscopic appearance of the colon.
The characteristics of the three groups of patients studied
are reported in Table 1.
Stool calprotectin
Figure 1 shows the individual concentrations of fecal cal-
protectin in the three groups of patients studied. Significant
differences were observed among the three groups
(P = 0.007) studied. In particular, the stool calprotectin
concentration was 17.4 ± 24.5 lg g–1 for patients with
colonic polyposis and this figure was significantly higher
than that found for patients with diverticulosis (calprotectin
7.1 ± 5.7 lg g–1; P = 0.026) and for subjects with normal
endoscopic appearance of the colon (calprotectin
6.0 ± 5.8 lg g–1; P = 0.003). Fecal calprotectin concen-
trations for patients with diverticulosis were similar to
those for subjects with normal endoscopic appearance of
the colon (P = 0.516).
The 16 patients with single polyp had stool calprotectin
concentrations (mean ± SD 20.1 ± 29.7 lg g–1; median
10.7 lg g–1 range 1.0–117.7 lg g–1) similar to those with
more than one polyp (mean ± SD 13.2 ± 12.7 lg g–1;
median 10.3 lg g–1 range 3.1–46.2 lg g–1; P = 0.830).
For these patients, after the exclusion of two patients (one
with a pedunculate polyp and one with a semipedunculate
polyp), the calprotectin fecal concentration was not sig-
nificantly different for the eight patients with sessile polyps
(mean ± SD 27.5 ± 41.3 lg g–1; median 7.6 lg g–1, range
3.1–117.7 lg g–1) and the six patients with flat polyps
(mean ± SD 11.9 ± 9.1 lg g–1; median 10.7 lg g–1, range
1.0–23.5 lg g–1; P = 0.556), and it was not significantly
related to the size of the polyps (P = 0.097; Pearson’s r).
Discussion
It has been reported that colorectal cancer is associated
with a local acute inflammatory reaction revealed by use of
leukocyte scanning and histology [18]. Calprotectin, a
stable neutrophil-specific marker, has also been shown to
be a simple and sensitive marker of colorectal cancer [19,
20]. Information about colonic polyps is scarce, however.
We undertook this study to explore the significance of fecal
calprotectin in polypoid lesions of the colon. With regard
to selection of patients, we found that those with a normal
endoscopic appearance of the colon were younger and had
a lower BMI than those with colonic polyposis and those
Table 1 Characteristics of the three groups of patients studied
Polyposisa (n = 26) Diverticulosisa (n = 17) Normala (n = 20) P value
Sex 0.466b
Males 15 (57.7%) 11 (64.7%) 9 (45.0%)
Females 11 (42.3%) 6 (35.3%) 11 (55.0%)
Age (years) 61.9 ± 7.6de 62.8 ± 10.0df 56.2 ± 10.6ef 0.057c
BMI (kg m–2) 25.9 ± 3.9gh 25.6 ± 4.7gi 23.0 ± 3.2hi 0.032c
Data are reported as mean ± SD values and frequencies
a Polyposis: patients with colonic polyps; Diverticulosis: patients with asymptomatic diverticulosis; Normal: subjects with a normal endoscopic
appearance of the colon
b v2 test
c One-way ANOVA
Comparison between pairs of groups (simple contrasts were applied): Polyposis compared with Diverticulosis: dP = 0.747, gP = 0.799; Polyposis
compared with Normal: eP = 0.042, hP = 0.013; Diverticulosis compared with Normal: fP = 0.033; iP = 0.044
1,000
1
100
10
µg
/g
Polyposis Diverticulosis Normal
Fig. 1 Individual stool calprotectin concentrations for the three
groups of patients studied: patients with colonic polyps (Polyposis),
patients with asymptomatic diverticulosis (Diverticulosis), and
subjects with normal endoscopic appearance of the colon (Normal).
Mean ± SD values are also reported. The horizontal dashed line
indicates the upper reference limit
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with asymptomatic diverticulosis. These findings are sim-
ilar to literature reports regarding age [21, 22] and BMI
[23, 24].
With regard to the main objective of our study, evalu-
ation of the significance of stool calprotectin concentra-
tions in patients with colonic polyps, we found that this
fecal index of inflammation was significantly higher for
patients with colonic polyposis than for those with diver-
ticulosis and those for subjects with a normal endoscopic
appearance of the colon. This finding confirms—by anal-
ysis of calprotectin, a simple and easy-to-measure mar-
ker—that inflammatory expression progressively increases
as epithelial cells progress from a normal colonic epithe-
lium to one containing polyps [6]. The concentrations of
fecal calprotectin for patients with a single polyp and those
with multiple polyps were not significantly different,
suggesting that the inflammatory response is not related to
the number of the polypoid lesions. To evaluate whether
calprotectin concentrations are related to the endoscopic
appearance of polyps, we measured fecal calprotectin
concentrations for patients with single polypoid lesions and
found that the calprotectin concentration was not signifi-
cantly for patients with sessile polyps and those with flat
polyps; in the same group of patients we also found that
calprotectin concentration was not related to the size of the
polyps. These findings may suggest the inflammatory
response is not related to the type or size of polypoid
lesions but is probably related to the immunological status
of the patient.
In conclusion, this study demonstrated that the presence
of colonic polyps may increase stool calprotectin concen-
trations, which suggests that these colonic lesions should
be suspected in cases of elevated stool calprotectin con-
centrations. Further studies are needed to confirm this
initial promising observation.
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